A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Trial Profile

A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs ISC-hpNSC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Cyto Therapeutics
  • Most Recent Events

    • 09 May 2017 According to an International Stem Cell Corporation media release, the company received approval to start second cohort (patients receiving higher dose of 50,000,000 of ISC-hpNSC) from Data Safety Monitoring Board after reviewing safety data from the first cohort.
    • 04 May 2017 Results from this trial will be presented at the American Society of Gene & Cell Therapy 20th Annual Meeting, according to an International Stem Cell Corporation media release.
    • 28 Apr 2017 Preliminary results assessing safety and functional activity of human pluripotent stem cell derived neural stem cells, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top